FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation. - Wikidata - wikimedia - TriplyDB

FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation.

FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation.

http://www.wikidata.org/entity/Q46815880

about

Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer Clinical significance of MET in gastric cancer HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.MET in gastric cancer--discarding a 10% cutoff rule The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study.Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab Clinicopathological Significance and Diagnostic Accuracy of c-MET Expression by Immunohistochemistry in Gastric Cancer: A Meta-Analysis.Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer.Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma.Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications.Endoscopic biopsies from gastrointestinal carcinomas and their suitability for molecular analysis: a review of the literature and recommendations for clinical practice and research.Therapeutic targeting of fibroblast growth factor receptors in gastric cancer.Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?Biomarker and Pathologic Predictors of Cutaneous Squamous Cell Carcinoma Aggressiveness.The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.C-Met as a Molecular Marker for Esophageal Squamous Cell Carcinoma and Its Association with Clinical Outcome.Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.Chromosomal breaks at FRA18C: association with reduced DOK6 expression, altered oncogenic signaling and increased gastric cancer survival.Biomarkers of gastric cancer: Current topics and future perspective A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas

P2860

Q26764932-AD1B2012-23C5-4477-9B62-42382330FA0D Q26776190-3AD2C038-A96D-45B6-A800-7B96E7F19FFA Q33917507-CCC3597F-7B9A-40FA-9CDD-5FD13F558F5A Q36554574-4895E836-EE0B-4BFF-8DFB-8AA913E05EF3 Q37302936-1E7824DF-D202-4F01-AE48-2EC8BED369EB Q37335124-182401AA-32A9-40B7-8875-1F91AC455096 Q37342442-029F299C-A6D1-47B0-8067-01B97A2A7009 Q37567109-5217BACE-E25B-4C91-94BA-398B618BE1EA Q37687784-1D332C90-2BA3-477A-86DF-74F07DDE90E1 Q37705824-8435F16F-CDAC-43B7-A652-21096BAA5C9E Q38263575-AA901A7A-EFD5-4A1A-9F09-99D522C41666 Q38272251-4E3BD1F3-BD83-456B-9CA3-5020A5AEDC63 Q38497265-DE19C3BE-20DB-43CE-A005-D1F1B32EE440 Q38741697-CE97A3EC-857F-453D-A3D9-33CAB1355E35 Q38812369-010ECF92-71CD-42D9-ADBA-82206FCC7F3D Q38824065-6F73DCF2-6D4D-4DFD-BD89-8053479A16E3 Q39866108-03C9F514-6838-4941-9BBF-603E6BBEB8B2 Q50985091-BA873B85-D442-4D8C-A8BA-0FFAED5887EB Q54218339-6DA68061-283A-43D9-BCC7-763504B23674 Q54976924-5D0B34BF-CD03-4A47-BB03-DBA26B762BDC Q57176090-0A235FBD-925C-4553-B157-4D257CBC3285 Q58763391-2B1EEAA1-513D-488A-8518-A17678E681F8

P2860

FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation.

http://www.wikidata.org/entity/Q46815880

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

FGFR2, HER2 and cMet in gastri ...... downstream pathway activation.

@en

FGFR2, HER2 and cMet in gastri ...... downstream pathway activation.

@nl

type

label

FGFR2, HER2 and cMet in gastri ...... downstream pathway activation.

@en

FGFR2, HER2 and cMet in gastri ...... downstream pathway activation.

@nl

prefLabel

FGFR2, HER2 and cMet in gastri ...... downstream pathway activation.

@en

FGFR2, HER2 and cMet in gastri ...... downstream pathway activation.

@nl

P1433

Q46815880-3FECDE76-D18C-4DF3-BC5F-9DC143B10547

P1476

Q46815880-EE9D7ABE-3589-435F-A641-FD5858758E79

P2093

Q46815880-04A17055-4A1A-4260-9DAC-9353C07B181F

Q46815880-0E19020A-CBD1-4500-8402-71D4C5A9A4A6

Q46815880-1C2F9655-4868-4E81-970B-7DE013A277E3

Q46815880-2F471F0E-2E73-4BAF-A68B-0BD4814B13C1

Q46815880-5E515B07-1FAF-4383-8049-DCADF671B8EF

Q46815880-78036FE6-5061-4992-8DD9-E9589BAD8DEA

Q46815880-C1F602B1-BB07-4EAA-90D0-DF28B9058989

Q46815880-CA46B9FF-A94A-47A3-8F8F-3944BBDCE064

P2860

Q46815880-00418DFB-8CE2-4452-A9B7-C2F11E445068

Q46815880-069FF7FC-982C-475D-9C11-FAA50FC4ABF6

Q46815880-1437466E-A8D5-4488-9B14-768250C72A49

Q46815880-1B6A2592-3381-4365-B7E3-9605C7838BB4

Q46815880-21AE1BE5-DC21-4C9E-BD5C-83FAD6584CC7

Q46815880-23783576-4DB0-4F9A-96FD-31332F802138

Q46815880-249C34E0-32CB-4CBF-84F4-32BF88DAE029

Q46815880-2A35BCF2-4D89-48F9-A95D-FB93F8B4B5B2

Q46815880-3C741337-7F1A-4999-984D-7FDE7D92A86D

Q46815880-43792369-7D7B-4164-A2A4-A1E08537C8CB

P2888

Q46815880-4DC56289-46F6-4507-B147-D7BE06654BC5

P304

Q46815880-557A6429-71E3-483E-9FC7-B18801A7601D

P31

Q46815880-E2441CC7-CA71-4287-8BA3-1A06E2C55D4D

P356

Q46815880-5704244D-2A6C-4606-8153-6495146B0512

P433

Q46815880-00DBF2F2-5E46-47E4-B31E-107E3934F7F4

P478

Q46815880-6A589436-3DDF-41CB-95FD-19789C8C631B

P50

Q46815880-E22BD486-7A2B-4BB1-A399-60FB672B0B9B

Q46815880-F29FA450-A808-4DC4-8C94-2BE0976FDFD3

P577

Q46815880-3440B5CC-AFA4-407F-A4D3-E0DDD0B624CA

P698

Q46815880-B85BD5CC-EFD6-45B7-81A3-B53F0CB40DCD

P921

Q46815880-338B8F7F-C651-40F1-AE05-C1671F4B6B4E

P356

S00428-013-1517-Y

P1433

Virchows Archiv

P1476

FGFR2, HER2 and cMet in gastri ...... downstream pathway activation.

@en

P2093

Christopher Womack

http://www.w3.org/2001/XMLSchema#string

Guy Betts

http://www.w3.org/2001/XMLSchema#string

Helen Valentine

http://www.w3.org/2001/XMLSchema#string

Ian Welch

http://www.w3.org/2001/XMLSchema#string

Richard Swindell

http://www.w3.org/2001/XMLSchema#string

Shethah Morgan

http://www.w3.org/2001/XMLSchema#string

Sue Pritchard

http://www.w3.org/2001/XMLSchema#string

Victoria Williams

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Tissue microarrays for high-throughput molecular profiling of tumor specimens

Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

Chemotherapy for advanced gastric cancer: across the years for a standard of care.

Molecular basis of gastric cancer development and progression.

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.

FGFR2 gene amplification and clinicopathological features in gastric cancer

Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy.

P2888

s00428-013-1517-y

P304

145-156

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00428-013-1517-Y

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

464

http://www.w3.org/2001/XMLSchema#string

P50

Ewen A Griffiths

Catharine M. West

P577

2013-12-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24306956

http://www.w3.org/2001/XMLSchema#string

P921